Search alternatives:
ng decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ng decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
341
-
342
-
343
-
344
-
345
-
346
-
347
-
348
-
349
-
350
Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs
Published 2022“…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
-
351
Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs
Published 2022“…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
-
352
-
353
-
354
-
355
-
356
-
357
Table_1_Cysteinyl Leukotriene Receptor Antagonists Associated With a Decreased Incidence of Cancer: A Retrospective Cohort Study.docx
Published 2022“…The cancer risk showed a tendency to decrease rapidly when LTRAs were used in high dose (aHR = 0.56, 95% CI = 0.40–0.79) or for longer durations of more than 3 years (aHR = 0.68, 95% CI = 0.60–0.76) and 5 years (aHR = 0.33, 95% CI = 0.26–0.42). …”
-
358
-
359
-
360